Racial disparity in taxane‐induced neutropenia among cancer patients
Open Access
- 21 September 2021
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 10 (19) , 6767-6776
Abstract
Background Large interindividual variations have been reported in chemotherapy-induced toxicities. Little is known whether racial disparities exist in neutropenia associated with taxanes. Methods Patients with a diagnosis of primary cancer who underwent chemotherapy with taxanes were identified from Vanderbilt University Medical Center's Synthetic Derivative. Multinomial regression models were applied to evaluate odds ratios (ORs) and 95% confidence intervals (CIs) of neutropenia associated with race, with adjustments for demographic variables, baseline neutrophil count, chemotherapy-related information, prior treatments, and cancer site. Results A total of 3492 patients were included in the study. Compared with White patients, grade 2 or higher neutropenia was more frequently recorded among Black patients who received taxanes overall (42.2% vs. 32.7%, p < 0.001) or paclitaxel (43.0% vs. 36.7%, p < 0.001) but not among those who received docetaxel (32.0% vs. 30.2%, p = 0.821). After adjustments for multiple covariates, Black patients who received chemotherapy with any taxanes had significantly higher risk of grade 2 (OR = 1.53; 95% CI = 1.09–2.14) and grade 3 (OR = 1.91; 95% CI = 1.36–2.67) neutropenia but comparable risk of grade 4 neutropenia (OR = 1.19; 95% CI = 0.79–1.79). Similar association patterns were observed for Black patients who specifically received paclitaxel, but a null association was found for those treated with docetaxel. Conclusion Black cancer patients treated with taxanes for any cancer had a higher risk of neutropenia compared with their White counterparts, especially those who received paclitaxel. More research is needed to understand the mechanism(s) underlying this racial disparity in order to enhance the delivery of patient-centered oncology.Keywords
Funding Information
- China Scholarship Council
- Vanderbilt Cancer Center
- National Institutes of Health (R01 HL133786)
- National Cancer Institute (K12 CA090625)
This publication has 33 references indexed in Scilit:
- Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyCancer, 2010
- Pharmacogenetics and pharmacogenomics of anticancer agentsCA: A Cancer Journal for Clinicians, 2009
- Neutropenia in 6 ethnic groups from the Caribbean and the U.S.Cancer, 2008
- Race and nutrition: an investigation of Black‐White differences in health‐related nutritional behavioursSociology of Health & Illness, 2007
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Association ofCYP2C8, CYP3A4, CYP3A5, andABCB1Polymorphisms with the Pharmacokinetics of PaclitaxelClinical Cancer Research, 2005
- Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114Journal of Clinical Oncology, 2004
- Chemotherapy‐induced neutropeniaCancer, 2004
- Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinomaCancer, 2003
- The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®)Cancer Treatment Reviews, 1993